SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-000826
Filing Date
2024-05-14
Accepted
2024-05-14 17:26:24
Documents
88
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fwbi-20240331x10q.htm   iXBRL 10-Q 1526507
2 EX-31.1 fwbi-20240331xex31d1.htm EX-31.1 11910
3 EX-31.2 fwbi-20240331xex31d2.htm EX-31.2 11923
4 EX-32.1 fwbi-20240331xex32d1.htm EX-32.1 7428
  Complete submission text file 0001410578-24-000826.txt   8319960

Data Files

Seq Description Document Type Size
5 EX-101.SCH fwbi-20240331.xsd EX-101.SCH 71009
6 EX-101.CAL fwbi-20240331_cal.xml EX-101.CAL 62660
7 EX-101.DEF fwbi-20240331_def.xml EX-101.DEF 324591
8 EX-101.LAB fwbi-20240331_lab.xml EX-101.LAB 620796
9 EX-101.PRE fwbi-20240331_pre.xml EX-101.PRE 497923
92 EXTRACTED XBRL INSTANCE DOCUMENT fwbi-20240331x10q_htm.xml XML 1329935
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37853 | Film No.: 24945901
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)